REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Save

Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR).

The study was a phase 3 multicenter, randomized, double-blind, placebo-controlled, international multicenter study testing SEC in active PMR. PMR patients were randomized to receieve either: SEC 300mg, SEC 150mg, or placebo PBO), with steroids (tapered of 24 weeks). This was a superiority trial with a 52 week primary endpoint of achieving sustained remission. 

Topline results showed that SEC achieved statistically significant and clinically meaningful sustained remission (primary endpoint) and all secondary endpoints at week 52. The study also showed significant reduction in steroid useage. Full results will be presented at an upcoming medical congress and submitted to regulatory agencies in 2026.